尼妥珠单克隆抗体注射液治疗口腔颌面—头颈部鳞癌专家共识

2021-08-01 中国肿瘤科相关专家小组(统称) 实用口腔医学杂志

口腔颌面- 头颈部恶性肿瘤发病率位居人类恶性肿瘤的第6 位,大部分患者就诊时已到局部晚期阶段,经过手术、放化疗后仍有很高比例的患者会发生局部复发和/或远处转移。

中文标题:

尼妥珠单克隆抗体注射液治疗口腔颌面—头颈部鳞癌专家共识

发布日期:

2021-08-01

简要介绍:

口腔颌面- 头颈部恶性肿瘤发病率位居人类恶性肿瘤的第6 位,大部分患者就诊时已到局部晚期阶段,经过手术、放化疗后仍有很高比例的患者会发生局部复发和/或远处转移。针对复发和/或转移性口腔颌面- 头颈部鳞癌患者,以EGFR 靶向治疗药物为基础的靶向化疗是目前一线治疗常规应用方案。国际上已批准的治疗头颈部肿瘤的靶向药物有尼妥珠单克隆抗体( 单克隆抗体,以下简称单抗) 和西妥昔单抗,目前西妥昔单抗的指南很多,而尼妥珠单抗在口腔颌面- 头颈部恶性肿瘤的应用尚无明确规范。本文结合文献及相关专家的经验,制定专家共识,对尼妥珠单抗的抗肿瘤机制以及目前临床应用情况进行阐述,制定了尼妥珠单抗治疗口腔颌面- 头颈部鳞癌的建议方案,供临床医师参考。

相关资料下载:
[AttachmentFileName(sort=1, fileName=尼妥珠单克隆抗体注射液治疗口腔颌面—头颈部鳞癌专家共识.pdf)] GetToolGuiderByIdResponse(projectId=1, id=82e211c00220e5a1, title=尼妥珠单克隆抗体注射液治疗口腔颌面—头颈部鳞癌专家共识, enTitle=, guiderFrom=实用口腔医学杂志, authorId=0, author=, summary=口腔颌面- 头颈部恶性肿瘤发病率位居人类恶性肿瘤的第6 位,大部分患者就诊时已到局部晚期阶段,经过手术、放化疗后仍有很高比例的患者会发生局部复发和/或远处转移。, cover=https://img.medsci.cn/20211015/1634305620081_5579292.jpg, journalId=0, articlesId=null, associationId=747, associationName=中国肿瘤科相关专家小组(统称), associationIntro=null, copyright=0, guiderPublishedTime=Sun Aug 01 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">口腔颌面- 头颈部恶性肿瘤发病率位居人类恶性肿瘤的第6 位,大部分患者就诊时已到局部晚期阶段,经过手术、放化疗</span><span style="color: #373737;">后仍有很高比例的患者会发生局部复发和/或远处转移。针对复发和/或转移性口腔颌面- 头颈部鳞癌患者,以EGFR 靶向治疗药</span><span style="color: #373737;">物为基础的靶向化疗是目前一线治疗常规应用方案。国际上已批准的治疗头颈部肿瘤的靶向药物有尼妥珠单克隆抗体( 单克隆抗</span><span style="color: #373737;">体,以下简称单抗) 和西妥昔单抗,目前西妥昔单抗的指南很多,而尼妥珠单抗在口腔颌面- 头颈部恶性肿瘤的应用尚无明确规</span><span style="color: #373737;">范。本文结合文献及相关专家的经验,制定专家共识,对尼妥珠单抗的抗肿瘤机制以及目前临床应用情况进行阐述,制定了尼妥</span><span style="color: #373737;">珠单抗治疗口腔颌面- 头颈部鳞癌的建议方案,供临床医师参考。</span></p>, tagList=[TagDto(tagId=24083, tagName=头颈部鳞癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=31, categoryName=口腔科, tenant=100), CategoryDto(categoryId=73, categoryName=头颈外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=24083, guiderKeyword=头颈部鳞癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5887, appHits=93, showAppHits=0, pcHits=597, showPcHits=5794, likes=4, shares=6, comments=3, approvalStatus=1, publishedTime=Fri Oct 15 23:31:43 CST 2021, publishedTimeString=2021-08-01, pcVisible=1, appVisible=1, editorId=5579292, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=FUNNYMAN, createdTime=Fri Oct 15 21:54:00 CST 2021, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Sat Jan 06 21:28:17 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=尼妥珠单克隆抗体注射液治疗口腔颌面—头颈部鳞癌专家共识.pdf)])
尼妥珠单克隆抗体注射液治疗口腔颌面—头颈部鳞癌专家共识.pdf
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1061209, encodeId=f9db106120983, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72e12392556, createdName=12338494m28暂无昵称, createdTime=Sun Oct 17 12:26:35 CST 2021, time=2021-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060977, encodeId=030c10609e779, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15af5509987, createdName=ms1000001560840768, createdTime=Sat Oct 16 10:27:23 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060916, encodeId=0b381060916ed, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644b2182796, createdName=1207866fm50(暂无昵称), createdTime=Sat Oct 16 08:00:05 CST 2021, time=2021-10-16, status=1, ipAttribution=)]
    2021-10-17 12338494m28暂无昵称

    不错

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1061209, encodeId=f9db106120983, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72e12392556, createdName=12338494m28暂无昵称, createdTime=Sun Oct 17 12:26:35 CST 2021, time=2021-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060977, encodeId=030c10609e779, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15af5509987, createdName=ms1000001560840768, createdTime=Sat Oct 16 10:27:23 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060916, encodeId=0b381060916ed, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644b2182796, createdName=1207866fm50(暂无昵称), createdTime=Sat Oct 16 08:00:05 CST 2021, time=2021-10-16, status=1, ipAttribution=)]
    2021-10-16 ms1000001560840768

    感谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1061209, encodeId=f9db106120983, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=72e12392556, createdName=12338494m28暂无昵称, createdTime=Sun Oct 17 12:26:35 CST 2021, time=2021-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060977, encodeId=030c10609e779, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=15af5509987, createdName=ms1000001560840768, createdTime=Sat Oct 16 10:27:23 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060916, encodeId=0b381060916ed, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644b2182796, createdName=1207866fm50(暂无昵称), createdTime=Sat Oct 16 08:00:05 CST 2021, time=2021-10-16, status=1, ipAttribution=)]
    2021-10-16 1207866fm50(暂无昵称)

    谢谢分享

    0